Clinical trials: recruiting
Neoplasms
A Study of JNJ-1761981 in Participants With Solid Tumors
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981.
- Trial name
- NCT07525141
- Testing
- JNJ-1761981, Cetrelimab
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Left-sided Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other…
- Trial name
- NCT07702032
- Testing
- Petosemtamab, Cetuximab, FOLFIRI
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 960 people
- Sponsor
- Genmab
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 24 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
Non-small Cell Lung Cancer (NSCLC)
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells.
- Trial name
- NCT07566052
- Testing
- Setidegrasib, Docetaxel
- Where
- 23 sites in United States, China and 1 more
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Cancer
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive…
- Trial name
- optINAVO (NCT07368998)
- Testing
- Inavolisib, Fulvestrant
- Where
- 34 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Prostatic Neoplasms
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the…
- Trial name
- NCT06095089
- Testing
- JNJ-78278343, JNJ-87189401, Apalutamide
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 355 people
- Sponsor
- Janssen Research & Development, LLC
Myopia, Myopia Progression
Children's Viewing Behavior
The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- NCT07229365
- Testing
- Novel spectacle lens design, Spectacle lens designs
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL)…
- Trial name
- QOLIBRI (NCT06299540)
- Testing
- Individual Physical Activity Intervention (IPAI), Ibrutinib
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Janssen Cilag S.A.S.
Metastatic Breast Cancer
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the…
- Trial name
- HLD-0117 (NCT07524855)
- Testing
- JNJ-101684362 (HLD-0117)
- Where
- 7 sites in United States, Australia
- Volunteers
- 170 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with…
- Trial name
- NCT07405801
- Testing
- Inavolisib, Ribociclib, Fulvestrant
- Where
- 59 sites in United States, Argentina and 10 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Thrombocytopenia, Neonatal Alloimmune
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Trial name
- FREESIA-3 (NCT06533098)
- Testing
- Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
- Where
- 38 sites in United States, Austria and 9 more
- Volunteers
- 50 people
- Sponsor
- Janssen Research & Development, LLC
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting…
- Conditions
- B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05365659
- Testing
- IKS03
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Iksuda Therapeutics Ltd.
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 49 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD.
- Trial name
- NCT06566170
- Testing
- Donanemab, Usual Care
- Where
- United States
- Volunteers
- 6,250 people
- Sponsor
- Eli Lilly and Company
EGFR-Mutant Non-Small Cell Lung Cancer
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth…
- Trial name
- REACH-EGFR (NCT07699328)
- Testing
- VRN110755
- Where
- 29 sites in Australia, Canada and 8 more
- Volunteers
- 315 people
- Sponsor
- Voronoi, Inc
Multiple Myeloma
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of…
- Trial name
- NCT05201781
- Testing
- Cilta-cel
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 295 people
- Sponsor
- Janssen Research & Development, LLC
Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06968845
- Testing
- LTI-03, Dry Powder Inhaler
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Rein Therapeutics
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Hallux Valgus
A Study of VIRTUGUIDE System and DePuy Synthes Lapidus Implant in Participants Undergoing Lapidus Procedure
The purpose of this study is to assess the surgeon experience and surgery outcomes in participants undergoing index Lapidus procedure for the correction of hallux valgus (a foot deformity where the big toe angles outward towards…
- Trial name
- NCT07567092
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- DePuy Synthes Products, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.